Skip to main content

Human gp130 Antibody

R&D Systems, part of Bio-Techne | Catalog # AB-228-NA

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AB-228-NA

Key Product Details

Species Reactivity

Human

Applications

Neutralization, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human gp130
Leu24-Glu619 (Glu619Asp)
Accession # P40189

Specificity

Detects human gp130 in direct ELISAs and Western blots.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human gp130 Antibody

Cell Proliferation Induced by Oncostatin M/OSM and Neutralization by Human gp130 Antibody.

Cell Proliferation Induced by Oncostatin M/OSM and Neutralization by Human gp130 Antibody.

Recombinant Human Oncostatin M/OSM (Catalog # 295-OM) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human Oncostatin M/OSM (0.8 ng/mL) is neutralized (green line) by increasing concentrations of Human gp130 Polyclonal Antibody (Catalog # AB-228-NA). The ND50 is typically 20-40 µg/mL.

Applications for Human gp130 Antibody

Application
Recommended Usage

Western Blot

1 µg/mL
Sample: Recombinant Human gp130 (Catalog # 228-GP)

Neutralization

Measured by its ability to neutralize Oncostatin M/OSM-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 20‑40 µg/mL in the presence of 0.8 ng/mL Recombinant Human Oncostatin M/OSM.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Reconstitution

Reconstitute at 1 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: gp130

Gp130, the common signal transducing receptor component shared by the functional receptor complexes of the IL-6 family of cytokines, belongs to the class I cytokine receptor family. Binding of IL-6 (IL-11) to either the membrane-anchored or soluble IL-6 R (IL-11 R) initiates the association of IL-6 R (IL-11 R) with gp130 which then undergoes homo-dimerization and signal transduction. With other IL-6 family cytokines, such as LIF and OSM, signal transduction is triggered by the hetero-dimerization of gp130 and LIF R or OSM R.

Gp130 is expressed in all organs examined. Soluble gp130, which apparently arises either from proteolytic cleavage of the membrane-bound receptor or from alternative splicing, has been detected in human serum. At the present time, the in vivo functions of soluble gp130 are not clearly understood. In in vitro experiments, natural or recombinant soluble gp130 has been shown to have inhibitory effects on OSM and CNTF activities.

References

  1. Narazaki, M. et al. (1993) Blood 82:1120.
  2. Taga, T. and T. Kishimoto (1997) Annu. Rev. Immunol. 15:797.

Long Name

Glycoprotein 130

Alternate Names

CD130, IL6ST

Entrez Gene IDs

3572 (Human); 16195 (Mouse); 25205 (Rat); 101926138 (Cynomolgus Monkey)

Gene Symbol

IL6ST

UniProt

Additional gp130 Products

Product Documents for Human gp130 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human gp130 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...